APHON and its community provide a variety of events to help you keep pace with advancements in pediatric hematology/oncology nursing. You can view APHON events, local chapter events, Pediatric Chemotherapy/Biotherapy Provider courses, industry events, upcoming webinars, or the calendar of all events. The calendar name will indicate which events you are viewing.
Current survival rates for most pediatric patients with a first relapse of acute lymphoblastic leukemia (ALL) are dismal. Treatment strategies for relapsed ALL include intensive chemotherapy often followed by hematopoietic stem cell transplant. Blinatumomab is a new targeted therapy that has shown promising clinical activity in early phase clinical trials in both adult and pediatric patients with relapsed ALL.
Blinatumomab is a bispecific T-cell engager linking CD19 positive B-cells, including ALL cells, with CD3 T-cells, inducing T-cell activation and apoptosis. Blinatumomab has a distinctive toxicity profile including cytokine release syndrome (CRS) and reversible neurotoxicity. The current COG AALL1331 study aims to determine if the addition of Blinatumomab will improve outcomes for pediatric patients with a first relapse of ALL. This session will review the COG AALL1331 protocol and will include discussion of Blinatumomab administration and highlight nursing care of patients enrolled on this trial.
Disclaimer: APHON does not participate in the planning or execution of the provider course or any local chapter activity, and does not endorse any material produced by local chapters.